Table 5.
Clinical trials utilizing AFSCs
|
| |||
| Registration code | Disease | Results | Starting date |
| NCT00344708 | Damaged ocular surfaces | Re-establish the integrity of ocular surface | 2006 |
| NCT02961712 | Myelopathy | Improvement of Osame's Motor Disability score | 2016 |
| NCT03107975 | Spastic cerebral palsy | Improvement in gross motor function | 2017 |
| NCT04414813 | Parkinson's disease | Dopaminergic neurons differentiation | 2019 |
| ACTRN12618000076279* | Ischaemic stroke | Reducing infarct volume | 2019 |
| NCT02912104 | Primary ovarian insufficiency | Transdifferentiated into granulosa cells | 2016 |
| NCT03223454 | Asherman's syndrome | Improvement in endometrial thickness and fertility | 2017 |
| NCT03207412 | Ovarian insufficiency | Improvement in mice fertility | 2017 |
| NCT03381807 | Refractory severe intrauterine adhesion | Improvement in endometrial thickness and fertility | 2017 |
| NCT02959333 | Bronchial fistula | Recovery of bronchial fistula | 2016 |
| ACTRN12614000174684 | Bronchopulmonary dysplasia | Rescue lung injury | 2014 |
| ACTRN12620000676910 p** | COVID-19-related respiratory failure | Improved lung dysfunction | 2019 |
| NCT03031509 | Nonunion of limb fracture | Osteogenic differentiation | 2017 |
| NCT03764228 | Acute graft-vs.-host disease | Preventing acute graft-vs.-host disease | 2018 |
| ACTRN12616000437460 | Hepatic fibrosis | Reduce liver fibrosis and stimulate regeneration of liver cells | 2017 |
| ACTRN12618001883202 | Crohn's disease | Change in nature, severity or frequency of disease | 2018 |
| AFSCs: Amniotic fluid stem cells,*the cell source was human amniotic epithelial stem cells except the specified reference. Which was human amnion stem cells. **All clinical trials was in 1 stage except the specified reference which was the 2 stage | |||